A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk

The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with a placebo in participants with obesity or overweight, type 2 diabetes, and increased cardiovascular risk.

Inclusion Criteria: * Have type 2 diabetes * Have a HbA1c value between ≥ 6.5% and ≤ 9.5% at screening * Are on stable treatment with an unchanged dose of at least 1 and no more than 4 antihyperglycemic therapies for at least 90 days before screening * Have an increased risk of cardiovascular events * Have a BMI ≥ 25.0 kg/m2 at screening * Have a stable body weight (\1 year before screening) * Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening) * Have type 1 diabetes * Have a history or diagnosis of New York Heart Association Functional Classification IV congestive heart failure * Have had within 60 days prior to screening: * acute myocardial infarction * stroke * hospitalization for congestive heart failure, or * coronary, peripheral, or carotid artery revascularization procedure * Have received treatment combining sulfonylurea and insulin within 90 days prior to screening